Navigation Links
Drug Crimes in Canada Cause Continuing Problems for Small Communities
Date:7/8/2009

TROIS-RIVIERES, Quebec, July 8 /PRNewswire/ -- The Narconon drug rehab program has noticed a trend of many drug addicts being involved with drug related charges due to their addiction. "You can have the everyday functioning addict who is battling a drug addiction, and just one day gets caught by police for possession of a small amount," comments Nick Hayes, a representative of Narconon Trois-Rivieres. "This is an all too common situation for many people who are involved in a drug addiction." More people are using illicit drugs in Canada, in fact Trois-Rivieres, Quebec, Canada, where the Narconon drug rehab program is located, is one of the leading cities in Canada for drug crimes. "There are so many youth in Trois-Rivieres who are addicted to different drugs like speed, ecstasy, marijuana, and even cocaine. These teens get caught up with the law and start heading down the wrong path at a very young age," says Nick.

With Canada being one of the top distributors and producers of synthetic drugs, according to the United Nations 2009 Drug Report, it makes sense for the illicit drug crimes to be on a continuous rise in the country. Even though marijuana is still the number one drug responsible for the majority of the drug crimes in Canada, other drugs such as ecstasy, crystal meth and cocaine, are catching up and are responsible for more drug crimes each year. Statistics Canada indicated drug crimes reaching over the 100,000 mark and that this was combined with the crime rate reaching a thirty-year low. This is an unusual turn that the crime rate reached a thirty-year low, but illicit drug crimes reach a thirty-year high. Various police forces believe that this is due to the police coming down on drugs that have caused opposite trends.

Victoria and Abbotsford, both located in British Columbia, and Trois-Rivieres and Gatineau, both located in Quebec, followed on the list. Youth drug crimes made up 19% of all the cases in
'/>"/>

SOURCE Narconon Trois-Rivieres
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ViewPoint Bank Funds Senior Crimestoppers Program at Meadows Health and Rehab Center in Dallas
2. Credit Card Companies Fueling Healthcare Associated Identity Theft (HAIT) Crimes
3. Expose on Crimes Against Humanity as Perpetrated by the Gerontological Elite Asks Is Consensus in Anti-Aging Medical Intervention An Elusive Expectation or A Realistic Goal?
4. Glucose metabolism and recidivism of severe violent crimes in alcohol intoxications
5. Breast cancer prevention practices vary across Canada
6. Canadas government funds $1.6M in modern geography to support public health decisions
7. Philanthropic Giving for Health Care Slows in 2006 in both U.S. and Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
8. Canada leads the way in contraceptive compliance
9. HHS Secretary Leavitt Signs Agreement With Canada to Improve Indigenous Health Care Delivery and Access
10. Diabetes Response Service Launches in U.S. and Canada
11. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2American Chemical Societys Weekly PressPac June 3 2009 8740 1American Chemical Societys Weekly PressPac June 3 2009 8740 2American Chemical Societys Weekly PressPac June 3 2009 8740 3American Chemical Societys Weekly PressPac June 3 2009 8740 4American Chemical Societys Weekly PressPac June 3 2009 8740 5American Chemical Societys Weekly PressPac June 3 2009 8740 6American Chemical Societys Weekly PressPac June 3 2009 8740 7American Chemical Societys Weekly PressPac June 3 2009 8740 8American Chemical Societys Weekly PressPac June 3 2009 8740 9American Chemical Societys Weekly PressPac June 3 2009 8740 10Warner Chilcott to Present at the Goldman Sachs 30th Annual Healthcare Conference 48171 1Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 1Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 2Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 3